 | |
| Clinical data | |
|---|---|
| Other names | IMB-115 |
| Drug class | Nociceptin receptor agonist |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H33N3O3 |
| Molar mass | 435.568 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Sunobinop (developmental code namesV117957;IMB-115) is a high affinity small moleculenociceptin receptor partial agonist.[1]
As of February 2024, it is under clinical investigation for the treatment ofinsomnia/alcohol use disorder,interstitial cystitis, andoveractive bladder syndrome.[2][3] It was previously also under investigation for the treatment offibromyalgia.[1]
Sunobinop has nanomolar affinity (Ki) and efficacy (EC50) at human recombinant nociceptin/orphanin-FQ peptide (NOP) receptors. It has a high degree of functional selectivity for the NOP receptor. Sunobinop is a low affinity antagonist at human mu and kappaopioid receptors, and is a low affinity weak partial agonist at human delta opioid receptors.[4]
Sunobinop was generally well tolerated in 3 studies involving 70 healthy subjects at doses that ranged from 0.6 to 30 mg. The most prominent adverse event was dose-dependent sedation/somnolence, which was more common at doses greater than 10 mg. In these studies, most of the absorbed sunobinop was excreted unchanged via rapid renal elimination.[5]
The safety and effectiveness of sunobinop has not been evaluated by the FDA. There is no guarantee that sunobinop will successfully complete development or gain FDA approval.[2]